Literature DB >> 12499335

Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function.

Lisa G Wood1, Dominic A Fitzgerald, Alexander K Lee, Manohar L Garg.   

Abstract

BACKGROUND: Oxidative stress, as measured by 8-iso-prostaglandin F(2)(alpha) (8-iso-PGF(2)(alpha)), and depleted antioxidant defenses were shown in stable cystic fibrosis (CF) patients. The plasma fatty acid status of CF patients was linked to oxidative stress after respiratory exacerbations.
OBJECTIVE: We examined changes in plasma 8-iso-PGF(2)(alpha), antioxidant defenses, plasma fatty acid status, and clinical markers resulting from short-term antioxidant supplementation.
DESIGN: Forty-six CF patients were randomly assigned to either group A [low dose of supplement (10 mg vitamin E and 500 micro g vitamin A)] or group B [high dose of supplement (200 mg vitamin E, 300 mg vitamin C, 25 mg beta-carotene, 90 micro g Se, and 500 micro g vitamin A)]. Plasma concentrations of 8-iso-PGF(2)(alpha), vitamins E and C, beta-carotene, zinc, selenium, and copper; plasma fatty acid composition; erythrocyte glutathione peroxidase (EC 1.11.1.9) and superoxide dismutase (EC 1.15.1.1) activities; lung function; and dietary intake were measured before and after 8 wk of supplementation.
RESULTS: Antioxidant defenses in group B improved, whereas those in group A did not: in groups B and A, the mean (+/- SEM) changes (Delta) in vitamin E were 10.6 +/- 1.5 and -1.9 +/- 0.9 micro mol/L, respectively (P < 0.001), (Delta)beta-carotene were 0.1 +/- 0.04 and -0.01 +/- 0.02 micro mol/L, respectively (P = 0.007), (Delta)selenium were 0.51 +/- 0.10 and -0.09 +/- 0.04 micro mol/L, respectively (P < 0.001), and (Delta)glutathione peroxidase activity were 1.3 +/- 0.3 and -0.3 +/- 0.6 U/g hemoglobin, respectively (P = 0.016). There were no significant differences between the groups in Delta8-iso-PGF(2)(alpha), (Delta)vitamin C, (Delta)fatty acid composition, (Delta)superoxide dismutase activity, (Delta)lung function, or (Delta)white cell count. Within group B, (Delta)beta-carotene correlated with (Delta)percentage of forced vital capacity (r = 0.586, P = 0.005), (Delta)selenium correlated with (Delta)percentage of forced expiratory volume in 1 s (r = 0.440, P = 0.046), and (Delta)plasma fatty acid concentrations correlated with (Delta)percentage of forced expiratory volume in 1 s (r = 0.583, P = 0.006) and Delta8-iso-PGF(2)(alpha) (r = 0.538, P = 0.010).
CONCLUSIONS: Whereas increased beta-carotene, selenium, and fatty acid concentrations are linked to improved lung function, increased plasma fatty acid concentrations are linked to oxidative stress. If oxidative stress is deemed to be important to the clinical outcome of CF patients, means of reducing oxidative stress while maintaining a high-fat, high-energy diet must be investigated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12499335     DOI: 10.1093/ajcn/77.1.150

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  20 in total

Review 1.  The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities.

Authors:  Zhi Huang; Aaron H Rose; Peter R Hoffmann
Journal:  Antioxid Redox Signal       Date:  2012-01-09       Impact factor: 8.401

Review 2.  Vitamin E supplementation in people with cystic fibrosis.

Authors:  Peter O Okebukola; Sonal Kansra; Joanne Barrett
Journal:  Cochrane Database Syst Rev       Date:  2017-03-06

3.  Sodium selenite ameliorates both intestinal and extra-intestinal changes in acetic acid-induced colitis in rats.

Authors:  Samar M Soliman; Walaa Wadie; Samia A Shouman; Afaf A Ainshoka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-04-14       Impact factor: 3.000

4.  Effect of Oral Lipid Matrix Supplement on Fat Absorption in Cystic Fibrosis: A Randomized Placebo-Controlled Trial.

Authors:  Virginia A Stallings; Joan I Schall; Asim Maqbool; Maria R Mascarenhas; Belal N Alshaikh; Kelly A Dougherty; Kevin Hommel; Jamie Ryan; Okan U Elci; Walter A Shaw
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-12       Impact factor: 2.839

5.  Bioavailability of a novel, water-soluble vitamin E formulation in malabsorbing patients.

Authors:  Konstantinos Papas; John Kalbfleisch; Ricky Mohon
Journal:  Dig Dis Sci       Date:  2007-01-10       Impact factor: 3.199

6.  Changes in Mineral Micronutrient Status During and After Pulmonary Exacerbation in Adults With Cystic Fibrosis.

Authors:  Moon Jeong Lee; Jessica A Alvarez; Ellen M Smith; David W Killilea; James F Chmiel; Patricia M Joseph; Ruth E Grossmann; Amit Gaggar; Thomas R Ziegler; Vin Tangpricha
Journal:  Nutr Clin Pract       Date:  2015-06-15       Impact factor: 3.080

Review 7.  Autoinflammatory disease in the lung.

Authors:  Thomas Scambler; Jonathan Holbrook; Sinisa Savic; Michael F McDermott; Daniel Peckham
Journal:  Immunology       Date:  2018-04-19       Impact factor: 7.397

8.  Retinol binding protein status in relation to ocular surface changes in patients with cystic fibrosis treated with daily vitamin A supplements.

Authors:  Malgorzata Mrugacz; Jolanta Tobolczyk; Alina Minarowska
Journal:  Eur J Pediatr       Date:  2004-11-20       Impact factor: 3.183

9.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

Review 10.  Anti-inflammatory therapies for cystic fibrosis-related lung disease.

Authors:  David P Nichols; Michael W Konstan; James F Chmiel
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.